Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
Aim: Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and echocardiographic parameters in HFrEF outpatients previously treated with optimized therapy. Methods: Forty-nine HFrEF...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | International Journal of Cardiology: Heart & Vasculature |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906720303547 |
| _version_ | 1819070563675537408 |
|---|---|
| author | Matteo Landolfo Federica Piani Daniela Degli Esposti Eugenio Cosentino Stefano Bacchelli Ada Dormi Claudio Borghi |
| author_facet | Matteo Landolfo Federica Piani Daniela Degli Esposti Eugenio Cosentino Stefano Bacchelli Ada Dormi Claudio Borghi |
| author_sort | Matteo Landolfo |
| collection | DOAJ |
| description | Aim: Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and echocardiographic parameters in HFrEF outpatients previously treated with optimized therapy. Methods: Forty-nine HFrEF outpatients were retrospectively included in the study. We collected data from transthoracic echocardiography and clinical assessment at baseline and after 3 ± 1 and 12 ± 1 months of treatment with SV. Results were also stratified by sex to analyse possible sex-based differences in reverse remodelling response to SV. Results: After 3 months of treatment we observed a significative improvement of both systolic and diastolic function with a reduction of left ventricular mass and relative wall thickness (RWT). At 12 months we observed a further improvement of all previous parameters, plus systolic pulmonary artery pressure (PAP) and left atrial (LA) diameter. In women, most of the echocardiographic parameters improved after SV initiation, but did not reach the statistical significance, except for left ventricular ejection fraction (LVEF), PAP and LA diameter. As for clinical parameters, SV improved New York Heart Association (NYHA) Class, systolic blood pressure and loop diuretic dosage with a mild but significative increase in serum creatinine and potassium. Conclusion: Our study showed significative reverse remodelling properties of SV with an improvement of LV volumes, mass and systo-diastolic function. NYHA Class, systolic blood pressure and loop diuretic dosage also improved with only mild increase in serum creatinine and potassium. Women showed a lesser extent of reverse remodelling compared with men. |
| first_indexed | 2024-12-21T17:07:56Z |
| format | Article |
| id | doaj.art-c2be229af6ab4299b4c9509829201f31 |
| institution | Directory Open Access Journal |
| issn | 2352-9067 |
| language | English |
| last_indexed | 2024-12-21T17:07:56Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Cardiology: Heart & Vasculature |
| spelling | doaj.art-c2be229af6ab4299b4c9509829201f312022-12-21T18:56:29ZengElsevierInternational Journal of Cardiology: Heart & Vasculature2352-90672020-12-0131100656Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fractionMatteo Landolfo0Federica Piani1Daniela Degli Esposti2Eugenio Cosentino3Stefano Bacchelli4Ada Dormi5Claudio Borghi6Department of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Corresponding author at: Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, Bologna, BO 40138, Italy.Cardio-Thoraco-Vascular Department, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, ItalyCardio-Thoraco-Vascular Department, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, ItalyCardio-Thoraco-Vascular Department, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, ItalyDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, ItalyAim: Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and echocardiographic parameters in HFrEF outpatients previously treated with optimized therapy. Methods: Forty-nine HFrEF outpatients were retrospectively included in the study. We collected data from transthoracic echocardiography and clinical assessment at baseline and after 3 ± 1 and 12 ± 1 months of treatment with SV. Results were also stratified by sex to analyse possible sex-based differences in reverse remodelling response to SV. Results: After 3 months of treatment we observed a significative improvement of both systolic and diastolic function with a reduction of left ventricular mass and relative wall thickness (RWT). At 12 months we observed a further improvement of all previous parameters, plus systolic pulmonary artery pressure (PAP) and left atrial (LA) diameter. In women, most of the echocardiographic parameters improved after SV initiation, but did not reach the statistical significance, except for left ventricular ejection fraction (LVEF), PAP and LA diameter. As for clinical parameters, SV improved New York Heart Association (NYHA) Class, systolic blood pressure and loop diuretic dosage with a mild but significative increase in serum creatinine and potassium. Conclusion: Our study showed significative reverse remodelling properties of SV with an improvement of LV volumes, mass and systo-diastolic function. NYHA Class, systolic blood pressure and loop diuretic dosage also improved with only mild increase in serum creatinine and potassium. Women showed a lesser extent of reverse remodelling compared with men.http://www.sciencedirect.com/science/article/pii/S2352906720303547Sacubitril valsartanEntrestoReverse remodellingSex differencesHeart failureEchocardiography |
| spellingShingle | Matteo Landolfo Federica Piani Daniela Degli Esposti Eugenio Cosentino Stefano Bacchelli Ada Dormi Claudio Borghi Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction International Journal of Cardiology: Heart & Vasculature Sacubitril valsartan Entresto Reverse remodelling Sex differences Heart failure Echocardiography |
| title | Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction |
| title_full | Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction |
| title_fullStr | Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction |
| title_full_unstemmed | Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction |
| title_short | Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction |
| title_sort | effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction |
| topic | Sacubitril valsartan Entresto Reverse remodelling Sex differences Heart failure Echocardiography |
| url | http://www.sciencedirect.com/science/article/pii/S2352906720303547 |
| work_keys_str_mv | AT matteolandolfo effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction AT federicapiani effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction AT danieladegliesposti effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction AT eugeniocosentino effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction AT stefanobacchelli effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction AT adadormi effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction AT claudioborghi effectsofsacubitrilvalsartanonclinicalandechocardiographicparametersofoutpatientswithheartfailureandreducedejectionfraction |